APP13007 utilises Formosa Pharma’s APNT nanoparticle formulation platform and contains clobetasol propionate, a superpotent corticosteroid.
APP13007 will be commercialised in key Middle East and North Africa (MENA) regions.
The deal comes after the ophthalmic suspension obtained approval from the US Food and Drug Administration (FDA) in March 2024.
The agreement includes upfront payments and milestone payments on meeting commercialisation and sales-based goals, other than additional considerations, throughout the deal’s term.
Read the original article on Pharmaceutical Technology.
